Genetic effects on promoter usage are highly context-specific and contribute to complex traits.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
08 01 2019
Historique:
received: 05 09 2018
accepted: 08 01 2019
pubmed: 9 1 2019
medline: 11 4 2020
entrez: 9 1 2019
Statut: epublish

Résumé

Genetic variants regulating RNA splicing and transcript usage have been implicated in both common and rare diseases. Although transcript usage quantitative trait loci (tuQTLs) have been mapped across multiple cell types and contexts, it is challenging to distinguish between the main molecular mechanisms controlling transcript usage: promoter choice, splicing and 3' end choice. Here, we analysed RNA-seq data from human macrophages exposed to three inflammatory and one metabolic stimulus. In addition to conventional gene-level and transcript-level analyses, we also directly quantified promoter usage, splicing and 3' end usage. We found that promoters, splicing and 3' ends were predominantly controlled by independent genetic variants enriched in distinct genomic features. Promoter usage QTLs were also 50% more likely to be context-specific than other tuQTLs and constituted 25% of the transcript-level colocalisations with complex traits. Thus, promoter usage might be an underappreciated molecular mechanism mediating complex trait associations in a context-specific manner.

Identifiants

pubmed: 30618377
doi: 10.7554/eLife.41673
pii: 41673
pmc: PMC6349408
doi:
pii:

Substances chimiques

RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : MR/L003120/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/13/30194
Pays : United Kingdom
Organisme : Wellcome
ID : WT098503
Pays : International
Organisme : Estonian Research Council
ID : MOBJD67
Pays : International
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Estonian Research Council
ID : IUT34-4
Pays : International
Organisme : British Heart Foundation Cambridge Centre of Excellence
ID : RE/13/6/30180
Pays : International
Organisme : Wellcome
ID : WT09805
Pays : International
Organisme : Wellcome
ID : WT099754/Z/12/Z
Pays : International

Informations de copyright

© 2019, Alasoo et al.

Déclaration de conflit d'intérêts

KA, JR, JD, DP, DG No competing interests declared, DF Since October 2015, Daniel F Freitag has been a full-time employee of Bayer AG, Germany

Références

Genome Biol. 2018 Mar 29;19(1):46
pubmed: 29598823
Nat Methods. 2010 Dec;7(12):1009-15
pubmed: 21057496
Am J Hum Genet. 2014 Apr 3;94(4):559-73
pubmed: 24702953
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
Genome Biol. 2011;12(3):R22
pubmed: 21410973
Biostatistics. 2012 Apr;13(2):204-16
pubmed: 22285995
Bioinformatics. 2015 Jul 15;31(14):2400-2
pubmed: 25617416
Nature. 2018 Sep;561(7721):127-131
pubmed: 30150773
Cell. 2016 Nov 17;167(5):1398-1414.e24
pubmed: 27863251
Mol Cell. 2018 Sep 6;71(5):858-871.e8
pubmed: 30078726
Nature. 2014 Mar 27;507(7493):462-70
pubmed: 24670764
Nat Genet. 2013 Dec;45(12):1452-8
pubmed: 24162737
Genome Biol. 2016 Apr 23;17:74
pubmed: 27107712
Nature. 2017 Jun 15;546(7658):370-375
pubmed: 28489815
PLoS Comput Biol. 2013;9(8):e1003118
pubmed: 23950696
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Commun. 2017 Aug 16;8(1):266
pubmed: 28814792
Science. 2016 Apr 29;352(6285):600-4
pubmed: 27126046
Nat Genet. 2012 Sep;44(9):981-90
pubmed: 22885922
Bioinformatics. 2012 Dec 15;28(24):3326-8
pubmed: 23060615
Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13924-9
pubmed: 25201977
Nat Methods. 2016 Jun;13(6):508-14
pubmed: 27018577
Nat Genet. 2015 Sep;47(9):979-986
pubmed: 26192919
Nucleic Acids Res. 2018 Jan 25;46(2):582-592
pubmed: 29202200
Nat Genet. 2013 Nov;45(11):1353-60
pubmed: 24076602
Theory Biosci. 2012 Dec;131(4):281-5
pubmed: 22872506
Cell. 2016 Oct 20;167(3):657-669.e21
pubmed: 27768889
Nat Genet. 2015 Apr;47(4):381-6
pubmed: 25751624
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2078-84
pubmed: 18802019
Nat Genet. 2019 Jan;51(1):128-137
pubmed: 30478436
Bioinformatics. 2012 Oct 1;28(19):2520-2
pubmed: 22908215
PLoS Genet. 2014 May 15;10(5):e1004383
pubmed: 24830394
Genome Res. 2014 Jan;24(1):14-24
pubmed: 24092820
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Nature. 2014 Feb 20;506(7488):376-81
pubmed: 24390342
Nat Genet. 2011 Nov 06;43(12):1193-201
pubmed: 22057235
Nat Genet. 2018 Jan;50(1):151-158
pubmed: 29229983
Genome Res. 2018 Dec;28(12):1812-1825
pubmed: 30446528
PLoS Genet. 2013;9(2):e1003270
pubmed: 23459209
Nat Biotechnol. 2015 Mar;33(3):290-5
pubmed: 25690850
Am J Hum Genet. 2015 Oct 1;97(4):567-75
pubmed: 26430802
Nature. 2017 Oct 11;550(7675):204-213
pubmed: 29022597
Genome Res. 2011 Aug;21(8):1260-72
pubmed: 21712398
Nat Genet. 2017 Sep;49(9):1385-1391
pubmed: 28714975
Sci Rep. 2015 Jul 30;5:12524
pubmed: 26224331
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Nat Biotechnol. 2016 Dec;34(12):1287-1291
pubmed: 27669167
Life Sci Alliance. 2019 Jan 17;2(1):
pubmed: 30655364
Am J Hum Genet. 2012 Nov 2;91(5):839-48
pubmed: 23103226
J Neurosci. 2013 Aug 14;33(33):13320-5
pubmed: 23946390
Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):E8181-E8190
pubmed: 30104386
PLoS Genet. 2017 Oct 23;13(10):e1007071
pubmed: 29059182
Science. 2014 Mar 7;343(6175):1246949
pubmed: 24604202
PLoS Genet. 2017 Oct 12;13(10):e1006995
pubmed: 29023442
Nature. 2013 Sep 26;501(7468):506-11
pubmed: 24037378
Nat Genet. 2016 Nov;48(11):1303-1312
pubmed: 27668658
Nat Genet. 2018 Mar;50(3):424-431
pubmed: 29379200
Nat Genet. 2015 Oct;47(10):1121-1130
pubmed: 26343387
Nat Genet. 2015 Dec;47(12):1457-1464
pubmed: 26502338
Genome Biol. 2018 Mar 28;19(1):45
pubmed: 29592814
Genome Res. 2009 Apr;19(4):567-75
pubmed: 19189928
Hum Mol Genet. 2015 Jun 15;24(12):3305-13
pubmed: 25743184
Bioinformatics. 2017 Sep 15;33(18):2938-2940
pubmed: 28645171
Elife. 2016 Feb 01;5:e11752
pubmed: 26829591
Genome Res. 2016 Aug;26(8):1145-59
pubmed: 27382025
Bioinformatics. 2015 Sep 1;31(17):2778-84
pubmed: 25926345
PLoS Genet. 2013 Jun;9(6):e1003594
pubmed: 23818875
Nat Commun. 2017 Nov 7;8(1):1358
pubmed: 29116076
Bioinformatics. 2014 Apr 1;30(7):1006-7
pubmed: 24351709
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
Bioinformatics. 2005 Aug 15;21(16):3439-40
pubmed: 16082012
PLoS Genet. 2017 Mar 6;13(3):e1006641
pubmed: 28263993
Elife. 2019 Jan 08;8:
pubmed: 30618377
BMC Genomics. 2013 Dec 17;14:892
pubmed: 24341889
Nat Rev Genet. 2014 Mar;15(3):163-75
pubmed: 24514444
Nat Commun. 2017 May 18;8:15452
pubmed: 28516912

Auteurs

Kaur Alasoo (K)

Institute of Computer Science, University of Tartu, Tartu, Estonia.
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.

Julia Rodrigues (J)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.

John Danesh (J)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom.
National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.

Daniel F Freitag (DF)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom.

Dirk S Paul (DS)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom.

Daniel J Gaffney (DJ)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH